Essex Bio-Technology Limited provided earnings guidance for the six months ended June 30, 2021. For the six months, the Group is expected to record a revenue of approximately HKD 737.4 million against approximately HKD 323.8 million for the corresponding period in 2020, representing an increase of approximately 127.7%; and an increase of not less than 225% in the net profit as compared to the corresponding period in 2020.